尿 microRNA-210-3p 作为一种新型的非侵入性生物标志物，用于检测胰腺癌，包括导管内乳头状黏液性肿瘤。

Urinary microRNA-210-3p as a novel and non-invasive biomarker for the detection of pancreatic cancer, including intraductal papillary mucinous carcinoma.

机构信息

Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii- cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.

出版信息

BMC Cancer. 2024 Jul 28;24(1):907. doi: 10.1186/s12885-024-12676-x.

DOI:10.1186/s12885-024-12676-x

PMID:39069624

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11283702/

Abstract

BACKGROUND

This study aims to explore novel microRNAs in urine for screening and predicting clinical characteristics in pancreatic cancer (PC) patients using a microRNA array-based approach.

METHODS

We used the Toray 3D-Gene microRNA array-based approach to compare urinary levels between PC patients and healthy volunteers.

RESULTS

(1) Four oncogenic microRNAs (miR-744-5p, miR-572, miR-210-3p, and miR-575) that were highly upregulated in the urine of PC patients compared to healthy individuals were identified by comprehensive microRNA array analysis. (2) Test-scale analysis by quantitative RT-PCR for each group of 20 cases showed that miR-210-3p was significantly upregulated in the urine of PC patients compared to healthy individuals (P = 0.009). (3) Validation analysis (58 PC patients and 35 healthy individuals) confirmed that miR-210-3p was significantly upregulated in the urine of PC patients compared to healthy individuals (P < 0.001, area under the receiver operating characteristic curve = 0.79, sensitivity: 0.828, specificity: 0.743). We differentiated PC patients into invasive ductal carcinoma (IDCa) and intraductal papillary mucinous carcinoma (IPMC) groups. In addition to urinary miR-210-3p levels being upregulated in IDCa over healthy individuals (P = 0.009), urinary miR-210-3p levels were also elevated in IPMC over healthy individuals (P = 0.0018). Urinary miR-210-3p can differentiate IPMC from healthy individuals by a cutoff of 8.02 with an AUC value of 0.762, sensitivity of 94%, and specificity of 63%. (4) To test whether urinary miR210-3p levels reflected plasma miR-210-3p levels, we examined the correlation between urinary and plasma levels. Spearman's correlation analysis showed a moderate positive correlation (ρ = 0.64, P = 0.005) between miR-210-3p expression in plasma and urine.

CONCLUSIONS

Urinary miR-210-3p is a promising, non-invasive diagnostic biomarker of PC, including IPMC.

TRIAL REGISTRATION

Not applicable.

摘要

背景

本研究旨在通过基于 microRNA 阵列的方法，探索尿液中新型 microRNAs，用于筛查和预测胰腺癌（PC）患者的临床特征。

方法

我们使用 Toray 3D-Gene microRNA 阵列方法比较 PC 患者和健康志愿者尿液中的 microRNA 水平。

结果

（1）通过综合 microRNA 阵列分析，发现 4 种致癌 microRNAs（miR-744-5p、miR-572、miR-210-3p 和 miR-575）在 PC 患者尿液中高度上调。（2）对 20 例每组的定量 RT-PCR 进行测试规模分析，结果显示 miR-210-3p 在 PC 患者尿液中显著上调（P=0.009）。（3）验证分析（58 例 PC 患者和 35 例健康个体）证实 miR-210-3p 在 PC 患者尿液中显著上调（P<0.001，ROC 曲线下面积=0.79，敏感性：0.828，特异性：0.743）。我们将 PC 患者分为浸润性导管癌（IDCa）和导管内乳头状黏液性癌（IPMC）组。除了 IDCa 患者尿液中的 miR-210-3p 水平明显高于健康个体（P=0.009）外，IPMC 患者尿液中的 miR-210-3p 水平也高于健康个体（P=0.0018）。miR-210-3p 可以通过截断值 8.02 将 IPMC 与健康个体区分开来，AUC 值为 0.762，敏感性为 94%，特异性为 63%。（4）为了检测尿 miR210-3p 水平是否反映血浆 miR-210-3p 水平，我们检测了尿与血浆水平之间的相关性。Spearman 相关分析显示血浆和尿液中 miR-210-3p 表达之间存在中度正相关（ρ=0.64，P=0.005）。